Home > Healthcare > Drug Device Combination > Therapeutic Systems > Plantar Fasciitis Treatment Market

Plantar Fasciitis Treatment Market Analysis

  • Report ID: GMI8660
  • Published Date: Mar 2024
  • Report Format: PDF

Plantar Fasciitis Treatment Market Analysis

The market by treatment type is categorized into therapy, medication therapy, and surgery. The therapy segment is further bifurcated into orthotic devices, shockwave therapy, ultrasound therapy, and other therapies. The orthotic devices segment garnered USD 229.9 million revenue in 2023.

  • Orthotic devices, such as foot orthotics and night splints, are designed to provide support, alignment, and cushioning to the foot, which helps in alleviating the symptoms of plantar fasciitis. By redistributing pressure and reducing strain on the plantar fascia, orthotic devices help to relieve pain, inflammation, and discomfort associated with the condition. The proven efficacy of orthotic devices in providing support and reducing symptoms makes them a popular choice among patients and healthcare providers for managing plantar fasciitis.
  • Furthermore, it offers a non-invasive treatment option for plantar fasciitis, which is often preferred by patients over more invasive interventions such as surgery. Foot orthotics, in particular, can be custom-made or off-the-shelf and are typically well-tolerated by patients. They provide an effective alternative to surgical procedures, with fewer risks, shorter recovery times, and lower costs.
  • As patient preferences shift towards non-invasive treatments, the demand for orthotic devices in the market continues to rise. This is anticipated to boost the segmental growth in the market positively.

Plantar Fasciitis Treatment Market, By Indication (2023)

Based on indication, the plantar fasciitis treatment market is segmented into mild, moderate, and severe. The mild segment accounted for over 62% business share in 2023 and is anticipated to witness significant growth during the forecast period.

  • Mild treatments, including conservative measures such as rest, stretching exercises, orthotic devices, and nonsteroidal anti-inflammatory drugs (NSAIDs), are often effective in managing mild cases of plantar fasciitis. These treatments help alleviate symptoms such as heel pain, inflammation, and stiffness while minimizing the risk of complications associated with more invasive interventions. The proven effectiveness and safety profile of mild treatments make them a preferred choice for patients and healthcare providers, particularly in the early stages of plantar fasciitis.

  • Moreover, the mild cases of plantar fasciitis are prevalent among individuals engaged in activities that place repetitive stress on the plantar fascia, such as running, walking, or standing for long periods. As the incidence of risk factors such as obesity, physical activity, and age-related changes in foot structure continues to rise, the prevalence of mild cases of plantar fasciitis is expected to increase. The high prevalence of mild cases drives the demand for effective and accessible mild treatments in the market.

The plantar fasciitis treatment market by end-use is categorized into hospitals, orthopedic clinics, physiotherapy centers, and other end-users. The hospitals segment accounted for around USD 675.9 million revenue size in 2023.

  • Hospitals are typically house specialized departments or clinics dedicated to orthopedics, podiatry, or sports medicine, where patients can receive comprehensive care from multidisciplinary teams of healthcare professionals. These facilities offer access to advanced diagnostic tools, treatment modalities, and surgical interventions that may not be available in other healthcare settings.
  • Additionally, the prevalence of severe or refractory cases of plantar fasciitis often necessitates hospital-based interventions, such as extracorporeal shockwave therapy (ESWT), radiofrequency ablation, or surgical procedures. Hospitals are equipped with state-of-the-art facilities and expertise required to manage these complex cases, attracting patients seeking specialized care and contributing to the utilization of hospital-based services in the market.

North America Plantar Fasciitis Treatment Market, 2020- 2032 (USD Million)

North America plantar fasciitis treatment market accounted for USD 498.4 million revenue in 2023 and is predicted to witness substantial market growth.

  • North America has a high prevalence of plantar fasciitis, with millions of individuals affected by this condition each year. Factors such as sedentary lifestyles, obesity, increasing participation in physical activities, and aging population contribute to the rising incidence of plantar fasciitis in the region. The high prevalence of plantar fasciitis drives demand for effective treatment options, including conservative therapies, advanced interventions, and surgical procedures, thereby fueling growth in the market.
  • Furthermore, the region has one of the highest healthcare expenditures globally, with substantial investments in healthcare infrastructure, research, and development. The region's healthcare expenditure fuels demand for innovative treatments and technologies for various medical conditions, including plantar fasciitis. Patients in North America have access to a wide range of treatment options, and healthcare providers are well-equipped to offer personalized and comprehensive care for individuals with plantar fasciitis, driving market growth and innovation.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Plantar fasciitis treatment industry size was USD 1.2 billion in 2023 and is set to expand at 9.3% CAGR from 2024-2032 driven by the ongoing advancements in technology, an increase in the prevalence of plantar fasciitis, and the rising demand for minimally invasive procedures

Plantar fasciitis treatment market from the orthotic devices segment generated USD 229.9 million in revenue in 2023 and is projected to witness high demand through 2032 as these devices are designed to provide support, alignment, and cushioning to the foot.

North America plantar fasciitis treatment industry size was USD 498.4 million in 2023 and is set to exhibit robust growth through 2032 owing to the surging need for effective treatment options, including conservative therapies, advanced interventions, and surgical procedures in the region.

Some of the top plantar fasciitis treatment companies are 3M, A. Algeo Ltd., Bauerfeind USA Inc., Hanger, Inc., OrthoBethesda, OrthoMed, Inc., Ottobock, Pfizer, Inc., Revance, Therapeutics, Inc., Sanofi, and Shapecrunch.

Plantar Fasciitis Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 441
  • Countries covered: 22
  • Pages: 230
 Download Free Sample